Compare CMCT & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCT | SCNI |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.9M |
| IPO Year | N/A | N/A |
| Metric | CMCT | SCNI |
|---|---|---|
| Price | $2.77 | $0.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.9M | 60.4K |
| Earning Date | 03-06-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $113,028,000.00 | $1,147,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.03 |
| Revenue Growth | N/A | ★ 303.87 |
| 52 Week Low | $2.56 | $0.61 |
| 52 Week High | $19.50 | $6.18 |
| Indicator | CMCT | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 41.41 |
| Support Level | $2.65 | $0.75 |
| Resistance Level | $3.05 | $0.86 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 6.90 | 13.87 |
Creative Media & Community Trust Corp is formed to invest in, own, and operate Class A and creative office investments in improving urban communities throughout the United States. It operates through segments such as office, hotel and multifamily properties and lending. The Office segment includes rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment relates to operations of hotel properties whereas, the lending segment refers to income from the yield and other related fee income earned on its loans receivable. The lending segment includes income recognized from the sale of government guaranteed portion of loans receivable, income from the yield on its loans receivable and other related fee income earned.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.